/ Direct To Patient (DTP)

/ Omnichannel

/ Go To Market Strategy & Optimization

/ Data & Analytics

/ Innovation applied

Big agency thinking at boutique agility.

Where strategy
meets the moment.

Pharma marketing, analytics and innovation in service of impact.

Talk with Aaron

Start a conversation today

Talk with Aaron

Start a conversation today

WHITE PAPER

WHITE PAPER

The DTP program launched. The channel didn’t.

Why some direct-to-patient programs plateau after go-live — and the four numbers that tell you what it is costing your brand.

INDUSTRY LANDSCAPE

The commercial model needs rewriting


Built for the moment the playbook stopped working.

Silent film worked until sound arrived. Video rental worked until streaming replaced it. The format before each transition wasn’t bad. It was insufficient for what came next.

These are the moments we were built for.

Commercial

33% meet or exceed

67% of pharma brands fail to meet launch expectations and sales forecasts, with 70% continuing to underperform three years post-launch.

Deloitte Center for Health Solutions, 2020

Commercial

33% meet or exceed

67% of pharma brands fail to meet launch expectations and sales forecasts, with 70% continuing to underperform three years post-launch.

Deloitte Center for Health Solutions, 2020

Omnichannel

53% HCP engagement

HCP field & digital engagement levels fell by 53% even as U.S. pharma ad spend has more than tripled to an estimated $39B.

Veeva Systems Pulse Field Trends, 2024

Omnichannel

53% HCP engagement

HCP field & digital engagement levels fell by 53% even as U.S. pharma ad spend has more than tripled to an estimated $39B.

Veeva Systems Pulse Field Trends, 2024

Direct to Patient (DTP)

50-point gap

72% said they would buy prescriptions directly from a manufacturer. Only 22% ever had. It is not a demand problem. It is a promotion problem.

Model N, 2025

Direct to Patient (DTP)

50-point gap

72% said they would buy prescriptions directly from a manufacturer. Only 22% ever had. It is not a demand problem. It is a promotion problem.

Model N, 2025

Patient Abandonment

98M lost new patients

98 million new therapy prescriptions were abandoned in 2023. 43 million of those were abandoned when the cost was under $10 or at no cost to the patient. Only 31% of patients were still on therapy a year later.

IQVIA, 2023

Patient Abandonment

98M lost new patients

98 million new therapy prescriptions were abandoned in 2023. 43 million of those were abandoned when the cost was under $10 or at no cost to the patient. Only 31% of patients were still on therapy a year later.

IQVIA, 2023

Innovation

50% of leaders want an overhaul

50% of global life-sciences leaders say they must completely abandon their traditional business model to enable innovation, accelerate decisions & stay competitive.

Deloitte Center for Health Solutions, 2020

Innovation

50% of leaders want an overhaul

50% of global life-sciences leaders say they must completely abandon their traditional business model to enable innovation, accelerate decisions & stay competitive.

Deloitte Center for Health Solutions, 2020

The advice is the product. The independence is the structure. The impact is the proof.
The advice is the product. The independence is the structure. The impact is the proof.
The advice is the product. The independence is the structure. The impact is the proof.

OUR SERVICES

Three questions.
Three offerings.


Most firms protect the relationship by telling clients what they want to hear. Clients hire us for the opposite: the uncomfortable, on-time truth, delivered while it’s still cheap to act on. With no platform to sell and no media to mark up.

THE DEVIL'S ADVOCATE

Is my thinking right?

Independent challenge to a idea, decision, or recommendation already on the table from launch plans to vendor selections or a board recommendation to a diligence thesis. We pressure-test the thinking, surface what’s been assumed rather than evidenced, and name the risks the team is too close to see. We don’t replace your team, we interrogate the thinking.

THE DEVIL'S ADVOCATE

Is my thinking right?

THE CONSIGLIERE

What should I do?

We are the senior commercial voice on call, before the board meeting, before the client pitch or before the decision is final. Engagements range from check-ins, ad-hoc consultations, slide content to written recommendations when the decisions warrant them. We bring a point of view, not just a critique, and stay accountable for the quality of the counsel.

THE CONSIGLIERE

What should I do?

THE PARTNER BY MANDATE

Can you do it with me?

Embedded senior commercial leadership against a written mandate. Our deepest commitment to a single client during their pre-launch year, a brand’s first eighteen months or addressing mid-cycle pressure points. This is not a fractional role billed by the day but a partner accountable for the trajectory of the mandate.

THE PARTNER BY MANDATE

Can you do it with me?

WHY THEY CHOOSE US

Decrease waste.
Increase wins.

Most firms protect the relationship by telling clients what they want to hear. Clients hire us for the opposite: the uncomfortable, on-time truth, delivered while it’s still cheap to act on. With no platform to sell and no media to mark up, the advice is the product — which is exactly why it can afford to be inconvenient.

Pharmacist reviewing product data on a tablet beside stocked medication shelves.

1. Life Sciences & Pharma

Focus on impact over activity at scale

Embracing both simplicity & sophistication simultaneously

A view free from internal politics

A presenter working through a strategy at a whiteboard while four colleagues listen.

2. The Vendors They Use

GTM positioning & story that lands with a buyer

A candid critique of the sales narrative

A clear answer quickly, with counsel that will tell you “don’t”

Three colleagues examining documents together across a boardroom table.

3. Private Equity

Diligence from a practitioner & subject matter expert

Spotting risk early

Exit readiness, from the commercial story

FAQ

Have questions?

Check out the FAQs

Have questions?

Check out the FAQs

Have questions?

Check out the FAQs

Talk with Aaron

Start a conversation today

Talk with Aaron

Start a conversation today

What does Kairos Meridian do?

We provide independent counsel while the decisions are still open, the strategy needs building, programs require sharpening, and new approaches demand exploration. The advice is our product.

What are your areas of expertise?

Commercial strategy in pharma & life sciences, with the deepest work in omnichannel, direct-to-patient, innovation, data and analytics.

What kind of businesses do you work with?

Small and mid-cap pharma brands in their first five years, the vendors selling into them, and the private equity firms holding related assets.

What don’t you do?

We don’t implement, staff, or execute what we recommend, which keeps the advice clean. No media buying, no campaign production, no downstream services and no junior consultants doing the thinking.

Are you a fractional executive service?

No. Fractional arrangements sell a percentage of someone’s time. We take interim leadership roles with a specific mandate, a defined goal, and an end date.

How do you price your projects?

Fixed fee, scoped to the question, the weight of the answer and operated with efficiency. Our pricing is not based on hours, headcount, and agency overhead.

An empty loft office with exposed timber beams and polished concrete.

The first conversation is twenty-five minutes — a diagnostic, not a pitch.

Start a conversation today

We listen for the real problem — how you got here, what you’ve tried, what success looks like — then come back with a structured read. The gap between the call and the response is where the senior judgment gets applied.